share_log

君聖泰醫藥-B(02511.HK)完成HTD1801治療2型糖尿病III期臨床試驗患者入組

Finet News ·  Jun 28 02:45

【財華社訊】君聖泰醫藥-B(02511.HK)公佈,公司自主研發的腸肝抗炎及代謝調節劑HTD1801(熊去氧膽小檗堿)針對2型糖尿病(T2DM)患者的2項III期臨床註冊試驗已完成患者入組。在該兩項試驗中,將評估HTD1801對T2DM患者糖化血紅蛋白及葡萄糖代謝、血脂、肝損傷/炎症標誌物及炎症等指標的作用。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment